FCGR3A and B-cell chronic lymphocytic leukemia: While the presence of the 158V allele has been shown to improve responses to rituximab in follicular lymphoma and Waldenstrom’s macroglobulinemia [73,74,75], data in CLL have shown that CD16 polymorphisms do not predict a response to rituximab monotherapy or FCR (combination fludarabine, cyclophosphamide, and rituximab) [76,77].